Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2012
10/16/2012US8287883 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
10/16/2012US8287877 Composition comprising immunogenic microparticles
10/16/2012US8287873 Vascular endothelial cell growth factor antagonists and uses thereof
10/16/2012US8287863 Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen
10/16/2012US8287857 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
10/16/2012CA2723823C Conjugates for the treatment of mesothelioma
10/16/2012CA2697077C 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
10/16/2012CA2648594C Solid oral dosage form containing an enhancer
10/16/2012CA2605680C Substituted amide derivatives as protein kinase inhibitors
10/16/2012CA2600195C Combinations for the treatment of cancer
10/16/2012CA2577550C Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
10/16/2012CA2574022C A method for preparing purified extract form wild ginseng showing anticancer activity and the composition comprising the same
10/16/2012CA2533753C Drug for cancer therapy
10/16/2012CA2516028C Conjugates comprising a cancer targeting molecule linked to a liver-expressed chemokine
10/16/2012CA2504933C Methods and compositions for treating cancer using proteasome inhibitors
10/16/2012CA2485794C Triptolide derivatives for modulation of apoptosis and immunosuppression
10/16/2012CA2480696C Peptide epitopes common to antigens of the same multigene family
10/16/2012CA2466773C Inhibitor oligonucleotides and their use for specific repression of a gene
10/16/2012CA2451847C A novel engineered superantigen for human therapy
10/16/2012CA2442648C Oncolytic virus therapy
10/16/2012CA2356257C Insulin-like growth factor (igf) i mutant variants
10/11/2012WO2012139112A1 Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
10/11/2012WO2012139019A2 New indolinone protein kinase inhibitors
10/11/2012WO2012139001A2 Kinase protein binding inhibitors
10/11/2012WO2012138938A1 Aminopyrazine compounds useful as inhibitors of tra kinase
10/11/2012WO2012138857A2 Methods and materials for reducing supression of immune function
10/11/2012WO2012138797A1 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
10/11/2012WO2012138715A2 Small molecule inhibitors of xbp1 splicing
10/11/2012WO2012138708A1 Mhc engagement and clip modulation for the treatment of disease
10/11/2012WO2012138691A2 Diagnosis and treatment of taxane-resistant cancers
10/11/2012WO2012138648A1 Compositions and methods for modulating lpa receptors
10/11/2012WO2012138599A2 Hepatocyte growth factor mimics as therapeutic agents
10/11/2012WO2012138475A1 Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
10/11/2012WO2012138453A1 Efficient protein expression in vivo using modified rna (mod-rna)
10/11/2012WO2012138297A1 Acetyltanshinone iia (ata) as anticancer agent
10/11/2012WO2012138246A1 Pharmaceutical composition for treating hyperproliferative diseases
10/11/2012WO2012138102A2 Dlk1-specific human antibodies and pharmaceutical composition containing same
10/11/2012WO2012138100A2 Activin receptor type ii b inhibitors comprising dlk1 extracellular water-soluble domain
10/11/2012WO2012138013A1 Paclitaxel-loaded polymeric nanoparticle and preparation thereof
10/11/2012WO2012137993A1 Antibodies against angiopoietins 1 and 2, and their use
10/11/2012WO2012137870A1 Novel imidazo-oxazine compound or salt thereof
10/11/2012WO2012137538A1 Cytotoxic t cell inducing composition
10/11/2012WO2012137089A1 Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
10/11/2012WO2012136997A1 G-quadruplex stabilising agent
10/11/2012WO2012136937A1 Zinc n-acetyl taurinate for the treatment of prostate cancer
10/11/2012WO2012136910A1 Derivatives of 4-arylcoumarin and 4-arylquinoline, therapeutic uses thereof and method for synthesising same
10/11/2012WO2012136857A1 Drug containing recombinant mistletoe lectins for treating malignant melanoma
10/11/2012WO2012136776A1 Imidazopyridazines as akt kinase inhibitors
10/11/2012WO2012136772A1 Fused pyrrole derivates as estrogen receptor ligands
10/11/2012WO2012136732A1 Treatment of multiple myeloma with masitinib
10/11/2012WO2012136722A1 Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof
10/11/2012WO2012136694A1 Pyridopyrazine derivatives and their use
10/11/2012WO2012136691A1 Pyridopyrazine derivatives and their use
10/11/2012WO2012136685A1 Methods and compositions for anti-vegf and anti-c-met therapy
10/11/2012WO2012136622A1 Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
10/11/2012WO2012136553A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
10/11/2012WO2012136549A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
10/11/2012WO2012136531A1 Substituted imidazopyridines and intermediates thereof
10/11/2012WO2012136519A1 Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
10/11/2012WO2012136144A1 Camptothecin derivatives having anti-tumor activity
10/11/2012WO2012136133A1 Use of a-nor-5alpha-androstane compounds for preparing anti-malignant tumor medicine
10/11/2012WO2012136125A1 Compound dual-release capsule formulation comprised of bromodihydroartemisinin and a fe2+ agent
10/11/2012WO2012136099A1 4-(substituted phenylamino)quinazoline derivative and preparation method therefor, pharmaceutical composition and use thereof
10/11/2012WO2012136080A1 Benzomorpholine derivatives, preparation method and use thereof
10/11/2012WO2012135970A1 Inhibitors of phosphatidic acid phosphohydrolase (pap), including d-propranolol and analogs thereof, alone or in combination with desipramine, for the treatment of cancers that depend on the epidermal growth factor receptor (egfr), oncogenic variants thereof and other members of the erbb/her family
10/11/2012WO2012135951A1 Oral enzyme compositions for intestinal delivery
10/11/2012WO2012118349A9 Differentiation and proliferation method for natural killer cells from cd14-positive monocytes
10/11/2012WO2012112869A3 Targeted cancer therapy using ets transcriptional inhibitors
10/11/2012WO2012111025A3 1,2,3-triazole containing artemisinin compounds and process for preparation thereof
10/11/2012WO2012107498A4 Lysine demethylase inhibitors for myeloproliferative disorders
10/11/2012WO2012105797A3 Structure having nanoantenna and method for manufacturing same
10/11/2012WO2012103457A3 Stilbene analogs and methods of treating cancer
10/11/2012WO2012098397A4 Combination therapy for cancer
10/11/2012WO2012097057A3 Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
10/11/2012WO2012093091A3 New saccharide mimics and their use as inhibitors of angiogenesis and metastasis formation
10/11/2012WO2012092114A3 Oxidosqualene cyclase as a protein target for anticancer therapeutics
10/11/2012WO2012085171A3 Pharmaceutical compositions of pyridinium and quinolinium derivatives
10/11/2012WO2012061428A3 Nicotinamides as jak kinase modulators
10/11/2012WO2011156464A8 Crystalline forms of kinase inhibitors
10/11/2012WO2011117668A9 Carbazole linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
10/11/2012US20120259187 Dynamic colorectal pdt application
10/11/2012US20120259151 Pyridopyrazine derivatives and their use
10/11/2012US20120259095 Monoclonal antibodies with enhanced adcc function
10/11/2012US20120259093 Expression of secreted human alpha-fetoprotein in transgenic animals
10/11/2012US20120259022 Pharmaceutical compositions providing enhanced drug concentrations
10/11/2012US20120259013 Liquid dosage forms of isotretinoin
10/11/2012US20120259005 BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use
10/11/2012US20120259004 Anti-cancer extract and compounds
10/11/2012US20120259001 Duplex Oligonucleotides with Enhanced Functionality in Gene Regulation
10/11/2012US20120258998 Fusion genes in gastrointestinal cancer
10/11/2012US20120258996 Novel ligands that modulate rar receptors
10/11/2012US20120258995 New Indolinone Protein Kinase Inhibitors
10/11/2012US20120258993 Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
10/11/2012US20120258991 Method of treating a cancer by administering a specified drug
10/11/2012US20120258987 Lysophosphatidic acid receptor antagonists
10/11/2012US20120258986 Olefin containing nuclear transport modulators and uses thereof
10/11/2012US20120258982 Adamantyl compounds
10/11/2012US20120258977 Inhibitors of e1 activating enzymes
10/11/2012US20120258975 Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof
10/11/2012US20120258967 Pi3 kinase inhibitors and uses thereof
1 ... 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 ... 2211